Get the Stockscreener App
5.86
2.82%
-0.17
After Hours:
5.86
Myriad Genetics Inc stock is traded at $5.86, with a volume of 1.14M.
It is down -2.82% in the last 24 hours and up +28.23% over the past month.
Myriad Genetics Inc is a molecular diagnostics and precision medicine company committed to advancing health and well-being for all. The company develops and commercializes molecular tests that help patients and providers uncover genetic insights. Its tests assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties, supporting earlier detection, more precise treatment, and lowering healthcare costs. Its tests include BRACAnalysis CDx, EndoPredict, FirstGene, Foresight, GeneSight, MyChoice CDx, MyRisk (cancer treatment), MyRisk (cancer risk), Prequel, Precise Tumor, Prolaris, and SneakPeek. The company operates in the US and Rest of World, with maximum revenue from the US.
See More
Previous Close:
$6.03
Open:
$6.09
24h Volume:
1.14M
Relative Volume:
0.72
Market Cap:
$553.47M
Revenue:
$829.00M
Net Income/Loss:
$-399.90M
P/E Ratio:
-1.3578
EPS:
-4.3159
Net Cash Flow:
$-23.20M
1W Performance:
+2.63%
1M Performance:
+28.23%
6M Performance:
-11.61%
1Y Performance:
+10.78%
1-Day Range:
$5.775
$6.15
1-Week Range:
$5.725
$6.255
52-Week Range:
$3.53
$8.59
Myriad Genetics Inc Stock (MYGN) Company Profile
Name
Myriad Genetics Inc
Sector
Industry
Phone
801-584-3600
Address
322 NORTH 2200 WEST, SALT LAKE CITY, UT
Compare MYGN vs TMO, DHR, IDXX, NTRA, A
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MYGN
Myriad Genetics Inc
|
5.86 | 569.52M | 829.00M | -399.90M | -23.20M | -4.3159 |
TMO
Thermo Fisher Scientific Inc
|
516.62 | 192.35B | 45.20B | 6.87B | 6.75B | 18.19 |
DHR
Danaher Corp
|
194.19 | 137.04B | 24.78B | 3.68B | 5.29B | 5.1743 |
IDXX
Idexx Laboratories Inc
|
570.25 | 44.57B | 4.45B | 1.10B | 1.06B | 13.59 |
NTRA
Natera Inc
|
281.27 | 40.64B | 2.50B | -226.32M | 71.51M | -1.6412 |
A
Agilent Technologies Inc
|
131.14 | 36.89B | 7.23B | 1.41B | 1.09B | 4.979 |
Myriad Genetics Inc Stock (MYGN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-21-25 | Downgrade | Scotiabank | Sector Outperform → Sector Perform |
| May-08-25 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| May-07-25 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Apr-09-25 | Downgrade | Guggenheim | Buy → Neutral |
| Mar-12-25 | Upgrade | Piper Sandler | Neutral → Overweight |
| Feb-12-25 | Initiated | Craig Hallum | Buy |
| Dec-10-24 | Initiated | UBS | Neutral |
| Dec-09-24 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Sep-19-24 | Initiated | Morgan Stanley | Equal-Weight |
| Aug-28-24 | Initiated | Wells Fargo | Overweight |
| Jun-27-24 | Initiated | Scotiabank | Sector Outperform |
| Jun-03-24 | Resumed | Jefferies | Underperform |
| May-08-24 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Dec-21-23 | Resumed | Piper Sandler | Neutral |
| Dec-19-23 | Initiated | Wells Fargo | Equal Weight |
| Dec-14-23 | Initiated | Guggenheim | Buy |
| Dec-13-23 | Initiated | Wolfe Research | Outperform |
| Jul-05-23 | Resumed | JP Morgan | Underweight |
| May-23-23 | Upgrade | Goldman | Sell → Buy |
| Jan-18-23 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Oct-06-22 | Initiated | Stephens | Equal-Weight |
| Oct-15-21 | Resumed | Cowen | Market Perform |
| Jun-15-21 | Initiated | Raymond James | Mkt Perform |
| Jun-03-21 | Initiated | Goldman | Sell |
| Sep-26-19 | Downgrade | BofA/Merrill | Neutral → Underperform |
| Aug-14-19 | Downgrade | Piper Jaffray | Overweight → Neutral |
| Aug-02-19 | Upgrade | BofA/Merrill | Underperform → Neutral |
| Aug-01-19 | Upgrade | Barclays | Underweight → Equal Weight |
| Jul-29-19 | Downgrade | Needham | Strong Buy → Hold |
| Jul-09-19 | Downgrade | Cowen | Outperform → Market Perform |
| Mar-12-19 | Reiterated | Needham | Strong Buy |
| Jan-03-19 | Initiated | Needham | Strong Buy |
| Nov-30-18 | Upgrade | Goldman | Sell → Neutral |
| Oct-10-18 | Upgrade | Piper Jaffray | Neutral → Overweight |
| Jul-11-18 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Mar-21-18 | Upgrade | Morgan Stanley | Underweight → Equal-Weight |
| Jan-29-18 | Initiated | Goldman | Sell |
| Jan-22-18 | Reiterated | Barclays | Equal Weight |
| Jan-05-18 | Initiated | BTIG Research | Buy |
| Oct-02-17 | Resumed | Leerink Partners | Mkt Perform |
| Aug-09-17 | Reiterated | Barclays | Equal Weight |
| Feb-08-17 | Upgrade | Ladenburg Thalmann | Sell → Neutral |
| Jan-18-17 | Initiated | Deutsche Bank | Sell |
| Oct-10-16 | Downgrade | Ladenburg Thalmann | Neutral → Sell |
View All
Myriad Genetics Inc Stock (MYGN) Latest News
New Large-Scale Meta-Analysis Demonstrates Strong Prognostic Performance of Myriad's Prolaris Biopsy Test in Localized Prostate Cancer - 富途牛牛
MYGN Stock Price, Quote & Chart - ChartMill
SERA PROGNOSTICS ANNOUNCES APPOINTMENT OF MARK CAPONE TO ITS BOARD OF DIRECTORS - BioSpace
Sera Prognostics adds former Myriad Genetics CEO to board By Investing.com - Investing.com South Africa
MYGNMyriad Genetics Inc Latest SEC Filings - Finviz
Sera Prognostics adds former Myriad Genetics CEO to board - Investing.com
Spotting Winners: Myriad Genetics (NASDAQ:MYGN) And Therapeutics Stocks In Q1 - Yahoo Finance
Myriad (MYGN) Soars 8.3%: Is Further Upside Left in the Stock? - Yahoo Finance
(MYGN) Risk Channels and Responsive Allocation - Stock Traders Daily
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Aga - The National Law Review
Price to sales forward of Myriad Genetics, Inc. – NASDAQ:MYGN - TradingView
Price to book forward of Myriad Genetics, Inc. – NASDAQ:MYGN - TradingView
Myriad Genetics, Inc. Actuals & Estimates (NASDAQ:MYGN) - TradingView
897518 Forecast — Price Target — Prediction for 2027 - TradingView
Price to earnings forward of Myriad Genetics, Inc. – LS:897518 - TradingView
Price to sales forward of Myriad Genetics, Inc. – LS:897518 - TradingView
Enterprise value to revenue forward of Myriad Genetics, Inc. – NASDAQ:MYGN - TradingView
Enterprise value to revenue forward of Myriad Genetics, Inc. – LS:897518 - TradingView
MYGN Forecast — Price Target — Prediction for 2027 - TradingView
Myriad Genetics, Inc. Actuals & Estimates (FWB:MYD) - TradingView
Myriad Genetics clears analyst hurdle, shares steady on NASDAQ - AD HOC NEWS
MYD Forecast — Price Target — Prediction for 2027 - TradingView
Why Is Myriad Genetics (MYGN) Stock Rocketing Higher Today - Yahoo Finance
Myriad Genetics Expands Availability of Precise MRD™ for Colorectal, Renal and Breast Cancers, Supported by New Publication - Sahm
Director at Myriad Genetics (MYGN) reports 195,507-share Common Stock stake - Stock Titan
Myriad Genetics expands cancer detection test availability By Investing.com - Investing.com Australia
Form 8K Myriad Genetics Inc For: 23 June By Investing.com - Investing.com Australia
MYGN PE Ratio & Valuation, Is MYGN Overvalued - Intellectia AI
Myriad Genetics expands cancer detection test availability - Investing.com
Myriad Genetics director Daniel Skovronsky resigns from board By Investing.com - Investing.com Australia
Myriad Genetics director Daniel Skovronsky resigns from board - Investing.com UK
MYRIAD GENETICS, INC. 8-K Filing: Key Company Information and SEC Compliance Details for June 2026 - Minichart
Myriad widens cancer test access as breast study bolsters its case - Stock Titan
Board member Skovronsky exits Myriad Genetics (NASDAQ: MYGN) - Stock Titan
Myriad Genetics Inc (MYGN) Valuation: PE, PB & Fair Value Analysis - TradingKey
Myriad Genetics Inc (MYGN) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Myriad Genetics StockAnalyst views and sector comparison on a quiet news day - Ad-hoc-news.de
Ovarian Cancer Diagnostics Market Size to Reach USD 8.08 Billion by 2035 | SNS Insider - GlobeNewswire Inc.
Myriad Genetics Inc (MYGN) Institutional Confidence - TradingKey
Myriad Genetics Inc (MYGN) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Myriad Genetics Inc (MYGN) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Myriad Genetics Inc (MYGN) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Myriad Genetics Inc (MYGN) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Myriad Genetics Inc Stock (MYGN) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.50%
0.00%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):